North America Organoids Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis.
No. of Pages: 121 | Report Code: BMIRE00032023 | Category: Life Sciences
No. of Pages: 121 | Report Code: BMIRE00032023 | Category: Life Sciences
The North America organoids services market size is expected to reach US$ 6,574.44 million by 2031 from US$ 1,640.88 million in 2024. The market is estimated to record a CAGR of 21.9% from 2024 to 2031.
The North America organoids services market is segmented into the US, Canada, and Mexico. In 2024, the US held the largest share of the market. The mounting number of patients suffering from chronic conditions and viral diseases, commercialization of organoid models, increasing activity in research and development, and innovations in stem cell research are the main factors propelling the organoid services market in North America.
Key segments that contributed to the derivation of the North America organoids services market analysis are type, application, and source.
Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently and avoid costly and time-consuming failures in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services. By creating organoids from a patient's cells, researchers can tailor drug testing to individual responses, improving the likelihood of treatment success through a personalized approach. The integration of advanced technologies, such as high-throughput screening platforms and automated image analysis, further enhances the capabilities of organoid screening services. With the integration of high-throughput screening and organoids, researchers can test many drug compounds efficiently, analyze results more accurately, and accelerate the drug discovery process. Thus, the global focus on innovative screening services, driven by the popularity of personalized medicine and the need for faster drug development, favors the growth of the North America organoids services market. In January 2024, HUB Organoids (HUB) launched IntegriGut Screen for the global market. This innovative screening service employs patient-derived organoid (PDO) Monolayers-organoid monolayers derived from inflammatory bowel disease (IBD) patients—allowing access to high-quality human data on epithelial barrier function and accelerating the development of novel IBD therapies.
Based on country, the North America Organoids Services Market comprises the US, Canada, and Mexico. The US held the largest share in 2024.
Companies in the organoid services market in the US are focusing on organic growth strategies to strengthen their foothold. In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to continue the development of next-generation 3D biology technologies that drive step-change reduction in preclinical to clinical drug attrition. Further, increasing research and development activities, rising demand for tissue engineering and organ transplantation, and high organoid adoption rate are driving the organoid services market in the country. Organoids have the potential to overcome several previous limitations associated with biomedical research studies focused on gaining mechanistic insights into human development, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine. Research funding and venture capital investments have significantly raised their contributions toward the development of human organoids. In November 2020, researchers from the USC Viterbi Department of Biomedical Engineering and the USC Keck School of Medicine's Department of Stem Cell Biology and Regenerative Medicine collaborated on a four-year National Science Foundation-funded project with an estimated valuation of US$ 1.5 million. With this project, the departments look forward to improving the process of brain organoid development, along with making end products more consistent and reliable for brain researchers.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 1,640.88 Million |
| Market Size by 2031 | US$ 6,574.44 Million |
| Global CAGR (2024 - 2031) | 21.9% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Some of the key players operating in the market include CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The North America Organoids Services Market is valued at US$ 1,640.88 Million in 2024, it is projected to reach US$ 6,574.44 Million by 2031.
As per our report North America Organoids Services Market, the market size is valued at US$ 1,640.88 Million in 2024, projecting it to reach US$ 6,574.44 Million by 2031. This translates to a CAGR of approximately 21.9% during the forecast period.
The North America Organoids Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Organoids Services Market report:
The North America Organoids Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Organoids Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Organoids Services Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Organoids Services Market
